https://www.selleckchem.com/pr....oducts/ici-118551-ic
Our data strongly suggest that IL-1 targeted neutralizing therapies used to treat inflammatory diseases in patients unlikely reduce host resistance to chronic P. aeruginosa infection. To determine the difference in rate of weight gain from birth to 5 years based on exposure to maternal group B streptococcal (GBS) intrapartum antibiotic prophylaxis (IAP). Retrospective cohort study of 13 804 infants. Two perinatal centres and a primary paediatric care network in Philadelphia. Term infants born 2007-2012, followed longitudi
Like
Comment
Share
